{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:41:21Z","timestamp":1789486881457,"version":"build-2803163510"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Recent randomized controlled trials (RCTs) have expanded the role of intravenous thrombolysis (IVT) into the extended time window (beyond 4.5\u202fh) using CT perfusion (CTP)-based patient selection. Following the inclusion of extended-window thrombolysis into the most recent edition of the American Heart Association Acute Ischemic Stroke Guidelines in 2026, these recently completed studies, EXTEND, HOPE, TRACE III, and OPTION, collectively must now inform the rapid clinical implementation of this treatment as we enter an age of precision medicine in the management of acute stroke. This mini-review seeks to address three core implementation challenges for patient selection when considering extended-window thrombolysis: (1) efforts to establish clinical pathways for patient selection should consider the phenotype of patients enrolled in extended-window thrombolysis RCTs in addition to enrollment criteria, (2) assessments of the safety of extended-window thrombolysis based on the best available evidence are reassuring, and (3) promising results from extended-window thrombolysis trials for distal and medium vessel occlusion (DMeVO) stroke patients, in concert with recent neutral endovascular therapy (EVT) trials for treating DMeVO stroke, have carved out a distinct role for IVT in this patient population. Herein, we aim to leverage the best available evidence to address these critical questions that vascular neurologists face as we work toward the clinical implementation of this trial evidence.<\/jats:p>","DOI":"10.3389\/fneur.2026.1928500","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:31:56Z","timestamp":1789479116000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["CT perfusion-guided thrombolysis in the extended window: from trial eligibility to individualized patient selection"],"prefix":"10.3389","volume":"17","author":[{"given":"Qing","family":"Hao","sequence":"first","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Ryan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Ikramuddin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Duke University School of Medicine","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa2402980","article-title":"Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy","volume":"391","author":"Xiong","year":"2024","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2025.12063","article-title":"Alteplase for acute ischemic stroke at 4.5 to 24 hours: the HOPE randomized clinical trial","volume":"334","author":"Zhou","year":"2025","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1056\/NEJMoa1813046","article-title":"Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke","volume":"380","author":"Ma","year":"2019","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1001\/jama.2026.0210","article-title":"Tenecteplase for acute non-large vessel occlusion 4.5 to 24 hours after ischemic stroke: the OPTION randomized clinical trial","volume":"335","author":"Ma","year":"2026","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.1161\/STR.0000000000000513","article-title":"Guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association\/American Stroke Association","volume":"57","author":"Prabhakaran","year":"2026","journal-title":"Stroke"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1474-4422(22)00484-7","article-title":"Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial","volume":"22","author":"Roaldsen","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1056\/NEJMoa2413344","article-title":"Alteplase for posterior circulation ischemic stroke at 4.5 to 24 hours","volume":"392","author":"Yan","year":"2025","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1161\/STROKEAHA.122.040540","article-title":"Hypoperfusion intensity ratio is correlated with the risk of parenchymal hematoma after endovascular stroke treatment","volume":"54","author":"Winkelmeier","year":"2023","journal-title":"Stroke"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1056\/NEJMoa2310392","article-title":"Tenecteplase for stroke at 4.5 to 24 hours with perfusion-imaging selection","volume":"390","author":"Albers","year":"2024","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1161\/STROKEAHA.124.049167","article-title":"Interfacility transfer for thrombectomy: a promising therapeutic window","volume":"56","author":"Seners","year":"2025","journal-title":"Stroke"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1016\/S0140-6736(24)00921-8","article-title":"Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial","volume":"403","author":"Coutts","year":"2024","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e214400","DOI":"10.1212\/WNL.0000000000214400","article-title":"Journal Club: endovascular therapy for patients with low NIHSS scores and Large vessel occlusion in the 6- to 24-hour window","volume":"105","author":"Peycheva","year":"2025","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s42466-025-00400-4","article-title":"Randomized controlled trials of endovascular therapy for acute ischemic stroke with medium or distal vessel occlusion: a study level metaanalysis","volume":"7","author":"Schellinger","year":"2025","journal-title":"Neurol Res Pract"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/STROKEAHA.118.023117","article-title":"Endovascular treatment: the role of dominant caliber M2 segment occlusion in ischemic stroke","volume":"50","author":"Compagne","year":"2019","journal-title":"Stroke"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa2514120","article-title":"Endovascular treatment of medium-vessel-occlusion strokes","volume":"394","author":"Hu","year":"2026","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1928500\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:31:57Z","timestamp":1789479117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1928500\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":16,"alternative-id":["10.3389\/fneur.2026.1928500"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1928500","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"article-number":"1928500"}}